BG Medicine and FDA to Conduct Joint Biomarker Discovery Study to Improve Prediction of Human Liver Toxicity in Drug Development Process

BG Medicine, Inc.

BG Medicine and FDA to Conduct Joint Biomarker Discovery Study to Improve Prediction of Human Liver Toxicity in Drug Development Process

October 25, 2005

Study to Provide Solutions to Primary Obstacles in the Development of New Pharmaceuticals

Waltham, Mass, October 25, 2005 – BG Medicine, a Massachusetts-based biotechnology research company, today announced the submission of a Cooperative Research and Development Agreement (CRADA) with the Food and Drug Administration’s National Center for Toxicological Research (NCTR), to jointly conduct a liver toxicity study designed to overcome one of the primary obstacles to the efficient development of safe and effective drugs. The study, Liver Toxicology Biomarker Study (LTBS), aims to discover biomarkers of human hepatotoxicity in the standard test used by pharmaceutical manufacturers in the initial stages of drug development.

Liver toxicity is the most common biological reason for drug failure in the development of new pharmaceuticals, affecting one in six drugs in development. The toxicity tests currently in use by drug companies have been unchanged for at least 40 years and often fail to identify human liver toxicity issues. Consequently, liver toxicity is often detected for the first time when drugs are in phase 2 of clinical testing after tens of millions of dollars or more have been spent on a drug.

On March 16, 2004 the FDA released a report, "Innovation/Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products," describing the “urgent need to modernize the medical product development process -- the Critical Path -- to make product development more predictable and less costly.” The proposed project addresses the liver toxicity issue highlighted in the Critical Path document as one of the obvious and priority areas for innovation.

The CRADA process is a standard procedure for studies the FDA undertakes in collaboration with private companies. The liver toxicity study has been designed by BG Medicine and the FDA with input from a number of pharmaceutical companies. The study will be funded by and conducted in collaboration with pharmaceutical manufacturers.

The research project leverages NCTR’s and BGM’s systems biology platforms for functional genomics, proteomics, metabolomics and computational analysis.

The LTBS will be conducted at the FDA’s NCTR laboratory in Jefferson, Arkansas and at BG Medicine in Waltham, Massachusetts. The study is open to participation by all pharmaceutical manufacturers. Participating companies will receive a paid-up perpetual license to any biomarkers discovered and access to all project data.

About BG Medicine

BG Medicine is pioneering the commercial application of Systems Pharmacology, which is based on scientific advances in the Systems Biology field. For more information about BG Medicine please visit www.bg-medicine.com.

Contact:

Chris Oake
Foghound
781-248-6513
coake@foghound.com